Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2014 · 10-Q
Revenue$1.79M$1.79M+546.9% vs Q1 2013 Net Income-$28.08M-$28.08MN/M vs Q1 2013 EPS Diluted-$0.27-$0.27N/M vs Q1 2013 Operating Income-$26,527,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$23,502,000N/M Margins · derivedOperating margin-1480.3%+9520.4 pt vs Q1 2013
Net margin-1566.7%+9565.0 pt vs Q1 2013
ended Mar 31, 2015 · filed May 5, 2015 · 35 d after period end